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INTRODUCTION
Nanoparticles' safety is an integral part of their development process. We regularly witness the publication of reports on their toxicity effects in vitro, which beg for the question of their significance in vivo (Oberdörster et al., 2005 ; Sayes et al., 2007) . A crucial point to answer is to what extent and at what rate nanoparticles enter the body and distribute in its various tissues. The issue is controversial because nanoparticles are larger than most molecules known to penetrate easily in the body, because there are little data on the topic, and because the few published results conflict, even for the same type of nanoparticles (Odajima et al., 2008) . Nemmar et al. (2002) and Mills et al. (2006) exposed healthy non-smoking volunteers to 99m technetium-labelled carbon nanoparticles (Technegas ® ) in similar conditions. Nemmar et al. concluded that nanoparticles translocated from the lung into the blood circulation. Mills et al., however, found no evidence to support that claim, reporting that most of their observed data were explained by the distribution of free technetium (Tc), unbound to nanoparticles.
They suggested many explanations for Nemmar et al. (2002) data, such as the need to ccount for free technetium kinetics and the fact that in imaging data, several overlapping regions contribute to radioactivity in the regions of interest. For instance, the radioactivity measured in liver is partially related to technetium concentration in the lung, the skin, the blood and adipose tissues. It seems consequently crucial to re-analyse Nemmar et al. data with tools able to analyse imaging data and estimate relevant kinetics parameters.
Therefore, we developed a physiologically based pharmacokinetic (PBPK) model, adapted to imaging data analysis, which proposes a realistic, even if simplified, description of the mechanisms of absorption, distribution and elimination of technetium-labeled nanoparticles and free technetium in the body. In PBPK models, the body is subdivided into various compartments representing specific organs linked by blood flows. Compartments are characterized by a set of parameters of physiological relevance (e.g., volume and blood perfusion rate) which play a crucial role in explaining the behavior of chemical substances in the body, and are invariant across substances. PBPK models offer great flexibility. In particular, they are adapted to extrapolations between species, routes or dose levels (Chiu et al., 2007) . The general PBPK model we proposed was applied to the Nemmar et al. inhalation study, with parameters estimation in a Bayesian context. The Bayesian approach is a suitable method in the context of mechanistic pharmacokinetic modelling, as they are well suited for efficient use of both data and prior knowledge regarding the compound or the physiology of the subjects. This permits a reliable parameter estimation for a complex PBPK model such as the one used there. Nemmar et al. collected Technegas ® distribution data on 5 healthy male volunteers from 24 to 47 years old. Technegas ® is an aerosol suspension of 99m Tc-labelled carbon particles produced in high purity argon. The size of individual particles was 5 to 10 nm, confirmed by electron microscopy. Volunteers were exposed to approximately 100 MBq of Technegas ® in 3 to 5 breaths. Blood radioactivity data were collected at 1, 5, 10, 20, 30, 45 and 60 minutes after Technegas ® inhalation, together with gamma-camera images of radioactivity distribution in the whole body measured at 5, 10, 20, 30 and 45 minutes. Three regions of interest (liver, stomach lumen, bladder content, i.e. urine) were defined on the images. We disposed of their intensity apportioned to liver intensity at 5 minutes. We did not use directly intensity apportioned to initial lung radioactivity, as shown in Nemmar et al. figure 2, because of the very high variability of this measurement among the five subjects.
MATERIALS AND METHODS

Data
PBPK Model
The basic model structure is presented in Figure 1 , with the whole systems of equations detailed in the Appendix. It subdivides the human male body into 24 compartments. This number of compartments have been included because imaging data analysis decompose imaging regions of interest into many compartments (See next paragraph). However, we used a common partition coefficient between organs and blood and the blood fluxes in organs were fixed to reference values to avoid overparametrisation of the model.
As PBPK models deal with organ concentrations, prior to parameters estimation, we had to relate the observed data (relative gamma emission intensity or radioactive decay counts) to organ concentrations. We defined regions of interest (ROIs) for various organs on a projection of a voxel-based anthropomorphic phantom (Zubal et al., 2001) . We then counted the voxels pertaining to the various tissues and empty space around the body in the volume defined by an ROI, and formed the ratios of those counts to the total number of voxel in the volume considered. Then, we could relate mathematically ROI intensity and concentrations in organs and blood (See Appendix).
In our model, intake of nanoparticles occurs initially through breathing. Particles are deposited in the upper respiratory tract and lungs. Some are rapidly transferred to the stomach, due to the swallowing of particles deposited in the mouth (Nemmar et al., 2002) . In our model, there was consequently a fixed initial condition with a fixed quantity of particles and free technetium in the stomach and a fixed one in the lung. As actual exposure dose was uncertain, this parameter was among the ones we estimated from the data. Technegas ® is not homogeneous. Indeed, part of the technetium is unbound and particles have different sizes, which can induce different kinetics. We distinguished between three different fractions: 99m Tc bound to small particles (i.e. able to translocate), 99m Tc bound to large particles (i.e. unable to translocate) and free 99m Tc. The concomitant distribution of 99m Tc in these three fractions was modeled. Large particles are assumed to remain at constant concentration in the lung and the stomach, as suggested by many publications (Mills et al., 2005; Wiebert et al., 2006) . Small particles and free 99m Tc in the lung can transfer to blood by diffusion. Moreover, free 99m Tc can translocate from the lung into the gastrointestinal tract as shown by Wiebert et al. (2006) . This was accounted for in the model, in which we also assumed that this translocation was possible for small nanoparticles. Once in the blood, small particles and free 99m Tc diffuse to the various compartments (except the brain, because Nemmar data show no transfer of 99m Tc to that organ). Elimination of free 99m Tc is supposed to occur by filtration to urine. During the time of exposure (60 min), the renal elimination of particle bound-99m Tc was neglected, as there was only free 99m Tc found in urine (Nemmar et al., 2002) . To facilitate parameters estimation, we assumed that all organs have the same blood over tissue partition coefficient value. Some studies have shown that accumulation of 99m Tc is similar in most of the organs (ICRP, 1999) .
Applying the law of mass conservation for each organ or tissues yields for each model a set of differential equations (see Appendix), which were solved by numerical integration using the Parameters specific to Technegas ® or to the experiments performed were treated as random variables in a Bayesian statistical framework (as detailed below), and their prior sampling distributions are given in Table 3 .
Statistical analysis
A statistical measurement error model and a population model were needed to assign values for some of the parameters given in Table 3 given their prior distributions and Nemmar et al.
data. The measurement error model described modeling errors and uncertainties in the data collection process (e.g., in the fraction of the particles immediately swallowed, imprecise quantity of inhaled Tc, approximate definition of the regions of interest scanned). Interindividual variability was quantified in the framework of a population model (Gelman et al., 1996; Bernillon and Bois, 2000) to try to account for the fact that the five subjects studied clearly differed from a kinetic standpoint (see for example in Figure 3 the differences in blood radioactivity counts between subjects given the same exposure).
For a given PBPK model, the measurement errors in blood radioactivity counts were assumed to be independent and log-normally distributed, with a geometric mean equal to the PBPK model predictions and a geometric standard deviation (GSD) of 1.05 (approximately 5% error). The same was assumed for the relative intensities in liver, stomach, and urine, but with a GSD of 1.15. Data likelihoods were therefore given by:
where the function F(X,θ) corresponds to a PBPK model with input X and parameters θ, and σ c is equal to either 1.05 or 1.15.
Pharmacokinetic models and error models were embedded in a hierarchical population structure, which considers that each subject's parameter values θ are drawn from a statistical distribution G with given population mean µ θ and variance σ θ . The proposed population model has two major components: the individual and the population levels. At the individual level, parameters θ were assumed to be normally or log-normally distributed with population means µ θ and standard deviations σ θ . Truncation bounds of the distributions were set on the basis of the limits for plausible values. The hierarchical population structure was only applied for the physiological parameters in Table 3 (fractions of lungs and volume of urine). The population distributions were normal, with normal distribution for population variances with a mean of 1.01 and a standard deviation of 1. In contrast, partition coefficients and percentage of free Tc and of small particles were considered only as population parameters (i.e., constant across subjects). Two parameters were added at individual level, the quantity of inhaled Tc, Q lung (0) and the fraction of the inhaled particles immediately swallowed, S_f.
Bayesian Inference via MCMC
The population model described above was fitted to the observed data with Bayesian techniques (Gelman et al., 1995) . The Bayesian approach yields a sample of parameter values from their joint posterior distribution. From Bayes' theorem, the joint posterior distribution of parameters is proportional to the prior distributions of parameters multiplied by the data likelihood. The posterior is then an update, using observed data, of what it is known about parameters prior to the experiment.
The first step of the Bayesian approach consists in defining prior distributions that quantify the information coming from expertise or from the scientific literature. Prior distributions on population parameters and their associated parameters are summarized in Table 3 . As little is known about nanoparticle kinetics, we generally used very wide uniform distributions to define chemical-specific parameters. We had prior information about the first-order transfer rate from lung to blood for free Tc (Klotzerke et al., 1996; Thomeer et al., 2002 ) so that we fixed K v_lung_1 at 0.04.
We obtained marginal posterior distributions of the model parameters in Table 3 by randomly sampling their values from the joint posterior distributions of all population and individual parameters, conditionally on the data from the 5 subjects. For this, we used Markov Chain
Monte-Carlo simulations (Gilks et al., 1996) (Gelman and Rubin, 1992) .
RESULTS
The We tried an alternative model with no particle (small or large) being able to reach blood circulation. This was performed by fixing at 0 the translocation rates for small particles. The resulting-Loglikelihood was doubled, and the time-courses of organ intensities and blood concentration were not captured by this alternative model, for all the subjects. Table 4 gives posterior distribution summaries for the population parameters of the model. It appears that only a small proportion of the technetium was free (6.7% of total technetium) but also that only a small proportion of the particles were able to reach blood circulation (12.7% of total particles). For both parameters, the standard deviation is less than 20% of the mean value, which shows that, despite the relative low number of subjects, it was possible to have an accurate estimate for these parameters. The translocation rate of particles from lung to blood was 2-fold lower than the one of free technetium. Elimination of free technetium was rapid and translocation of free technetium from the lung into the stomach was ten times lower than its translocation in the blood. Partition coefficients were comparable for particle-bound and free technetium. As for individual parameters (data not shown), most of the initial amount of particles were in the lung, less than 4% of initially inhaled particles having being swallowed. Estimated exposures ranged from 139 to 229 MBq, greater than but consistent with the estimate 100 MBq reported by Nemmar et al. (2002) . Indeed, there were many sources of variation relative to exposure. For instance, the number of breaths varied from 3 to 5.
DISCUSSION
The adverse effect of inhaled particles on the cardiovascular system have been suggested to result from pulmonary inflammation resulting in systemic consequences and/or the direct translocation of particles from the lungs into the systemic circulation (Seaton et al., 1995; Vermylen et al., 2005) . With respect to the possibility that ultrafine particles translocate from the pulmonary into the blood circulation, various studies have been conducted in different animal models. The amount of ultrafine particles that translocated into blood and extrapulmonary organs differs amongst these studies (Nemmar et al., 2001; Oberdörster et al., 2002; Takenaka et al., 2001) .
However, the issue of particle translocation in humans is still contradictory. Brown et al. (2002) studied the deposition and clearance for 2 h of an 60 nm technetium-99m-labeled aerosol in human volunteers, and found no significant radioactivity over the liver (1.3 ± 1.2%). This activity was attributed to scatter from the lung and/or overlap of lung parenchyma in the liver. Consequently, these authors excluded the occurrence of translocation and, although they did not measure radioactivity in blood, they challenged the conclusion of Moreover, when the aerosol was added to whole blood in vitro, two peaks were observed one staying at the application point and the other moving with the solvent front (smaller peak).
The radioactivity observed after Technegas inhalation consisted mainly in free pertechnetate, because additional in vivo oxidation may easily have occurred. No TLC analysis after the administration of free pertechnetate in humans or in vivo in animals has been reported by these authors.
These results contrasts with previous findings by Nemmar et al., also based on inhaling an aerosol of technetium-99m-labeled carbon particles, where particle-bound radioactivity (also assessed by TLC) was detected in blood already after 1 minute, reaching a maximum between 10 and 20 minutes, and remaining at this level up to 60 minutes. The TLC analysis obtained after adding blood with 99m Tc-carbon particles collected from the generator showed, at 1 min, only one peak that stayed at the origin. However, at 60 min, in addition to the peak at the origin, the presence of a smaller peak of radioactivity at the solvent front has been observed (suggestive of in vitro oxidation). Following Technegas inhalation, TLC of all blood samples showed, in addition to radioactivity having moved with the solvent front, a substantial proportion of radioactivity that stayed at the application point and corresponded to particle-bound 99m Tc. In contrast, there was only one peak at the solvent front after adding 99m Tc-pertechnetate to blood or in blood collected after the intratracheal administration of 99m Tc-pertechnetate to hamsters. Gamma camera images showed substantial radioactivity over the liver and other areas of the body. Consequently, the discrepancies between these two studies may be related to the Technegas particles (size and composition) from Technegas generators with a different history and age. While further studies with other types of radioactive labeling should clarify this issue, the PBPK model developed for 99m technetiumlabelled carbon nanoparticles is a useful approach aimed at evaluating the translocation of nanoparticles from lungs into the systemic circulation.
To our knowledge, our paper presents the first use of PBPK modeling to assess distribution of nanoparticles in humans, based on imaging data. It offers a reasonable description of Technegas ® kinetics in humans, with a relatively low number of parameters (12 parameters). We showed how information obtained from imaging could be coupled with blood concentration measurements to update kinetics parameters distribution in a Bayesian framework. We obtained similar results relative to free technetium kinetics than other studies (ICRP, 1999; Mills et al., 2005; Wiebert et al., 2006) , a high elimination rate through urine, and less than 5% of swallowed particles. The estimated fraction of unbound technetium (6.7%) was also very coherent with the one found by Mills et al. (2005) at approximately 5%.
From our study, it appears that passage of particles (of this size and specification) from lung into the blood circulation is likely to occur, for a small number of particles, with a rate of passage half the known rate for soluble 99m Tc. In the paper by Nemmar et al. (2002) , there was no attempt to quantify the proportion of particles likely to enter the circulation, but suggestions of possible high levels. However, we showed here, with the same data, that only a small proportion of the particles were able to translocate. Moreover in the paper by Nemmar et al. (2002) , the rapid and constant liver radioactivity they observed was presented as due to particles sequestration in Kupffer cells, with a relatively high level of radioactivity (around 10%). With our modeling approach, we showed that liver radioactivity was partly explained by the presence of lung tissues in the liver imaging region of interest. Moreover, there was no need for a specific high partition coefficient to fit the data. Wiebert et al. (2006) performed experiments with either stable or unstable labeling. In the first experiment, there was only around 0.1 % of initial deposited activity detected in blood as bound to particles after 80 minutes. This result is close to the Mills study. In contrast, in the experiment with one subject exposed to unstable labeling, around 6% of initial deposited activity was found in blood as bound to particles. This result is close to our estimate for Nemmar study. This suggests that the percentage of particles able to translocate is very dependent on the experimental design, even if high percentages are very unlikely.
The data used form the experiments described by Nemmar et al. were not specifically collected to perform PBPK modeling. We only had data on liver, urine, stomach and blood and they only extend to 60 minutes. Moreover, the data reported on the imaging were expressed as percentage of initial lung radioactivity which is a relative imprecise measure because it is only relative and not quantitative nor specific for chemical identity. The dataset contained data of a few organs; a more detailed set, with, in particular lung radioactivity time course, would have helped us in the model assessment procedure. We also looked, in the literature, for kinetics data on free Tc kinetics, and we could only get prior information about the rate of passage from lung into blood. More information on Tc kinetics, in particular on the partition coefficient, would permit to refine the assessment of the distribution and kinetics of free and bound 99m Tc in the model. The expectation is that this would not change our main conclusion that the observed translocation cannot be explained solely by the kinetics of free technetium.
To conclude, a model was developed that describes the inhalation and distribution of Techngas in humans as representative of carbon nanoparticles. Although lacking measured tissue-to-blood partition coefficients and independent verification to a secondary data, the modeling approach using Bayesian and MCMC techniques provides a reasonable description on which to base further model refinement.
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APPENDIX : PBPK model equations
The following equations are for the quantities Q of 99m Tc-labeled nanoparticles and free 99m Tc in each compartment. Quantities were expressed in MBq, which is the unit of radioactivity For adipose tissue, adrenals, bone marrow, brain, breast, heart, kidneys, muscles, other organs and tissues, pancreas, skin, spleen, testes and thyroid:
where F i are defined in Table 2 , and P i are tissue over blood partition coefficients (Table 3) .
For the lung:
where K v_lung and K m_lung are respectively the direct transfer rate from lung to blood and the translocation rate from lung to stomach lumen (in L/min). Initial dose in the lung, Q lung (0) is one of the parameters and is estimated from the data for each of the subjects.
For the liver, blood feeds from the arterial pool, spleen, pancreas, stomach and gut: 
where K e_renal is the urinary clearance rate (in L/min).
For arterial blood:
For venous blood:
where i designate the following organs or tissues: adipose tissue, adrenals, bone marrow, brain, breast, heart, kidneys, liver, muscles, other organs and tissues, skin, testes and thyroid
The gastro-intestinal tract is described by four compartments: lumen stom lumen stom lung lung m lumen stom
lumen gut lumen gut lumen stom lumen stom lumen gut
where F stom_lumen is the transport rate from the stomach lumen to the gut lumen (L/min). These transport rates were assumed to negligible during the experiment.
As part of the inhaled particles have been swallowed, we introduced a parameter (S_f) so that Q stom_lumen (0)= S_f.Q lung (0). This parameter is estimated for all subjects.
We had first to relate the observed data (relative gamma emission intensity or radioactive decay counts) to the above quantities or concentrations. We defined regions of interest (ROIs) for various organs on a projection of a voxel-based anthropomorphic phantom (The Zubal Phantom -Voxel-Based Anthropomorphic Phantoms -[http://noodle.med.yale.edu/zubal/index.htm]). We then counted the voxels pertaining to the various tissues and empty space around the body in the volume defined by an ROI, and formed the ratios of those counts to the total number of voxel in the volume considered.
The following table gives the fractions estimated (they do not add up to 1 since minor tissues and empty space are excluded): We account for the blood present in the organs, which contributes to the intensity of radioactivity of the studied organs. The blood volume per organ was obtained from Leggett and Williams (1995) who provide blood content in percentage of total blood volume for a reference middle-aged man. In the equations for intensity, we added the blood contribution when it could be substantial, i.e. in liver (31%), lung (140%), spleen (52%).
The intensities at time t in liver, stomach lumen and urine were computed similarly: 
where K intensity is a proportionality constant, K d is the decay rate constant for 99m Tc (0.001922 min -1 , ), and f(i,j) the fraction of tissue i present in a ROI labeled j.
V urine (t) is the volume of urine (in L) at time t, computed as:
where V urine (0) is the volume of urine (in L) in the bladder at the start of exposure and F urine is the urinary flow rate (L/min).
The recorded radioactivity counts in blood (in CPM/g of blood) where obtained from C ven (in MBq/L) by:
The number 60000 comes from the conversion from MBq/L in CPM/g. We described jointly the kinetics of small particles-bound-99m Tc and free 99m Tc. We introduced the fraction of 99m Tc bound, Bound, and the fraction of small particles, Small, as model parameters and defined two set of variables (the concentrations related to large particles-bound-99m Tc are constant over time, so that there is no use to define a set of variables for them). Variables Q i_0 corresponded to 99m Tc bound to small particles (i.e., labeled nanoparticles) in each compartment, with Q i_1 corresponding to free 99m Tc. Similarly, we defined concentration sets C i_0 and C i_1 in MBq/L.
The inhaled small particles-bound-99m Tc and unbound-99m Tc concentrations were functions of the total concentration inhaled C inh :
Equations 1 to 3, and 5 to 11 were duplicated (one set for bound 99m Tc, the other for free 99m Tc). Output equations 12 to 14 and 16 did not change, and the concentrations C adip , C lung , C liver , etc. of total 99m Tc which they use were at each time computed as the sum of the bound (to small and large particles) and free concentrations. 0.0129 ± 0.00437 f (lung,stom) 0.00564 ± 0.00327 K v_lung_0 (L/min) 0.0165 ± 0.000952 P _0 0.445 ± 0.0295 V u_zero (L) 0.0196 ± 0.00779 K m_lung (L/min) 0.0049 ± 0.000868 K e_renal_1 (L/min) 0.798 ± 0.134 P _1 0.499 ± 0.164 
